Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study

Background and rationale: Non-curative surgical cytoreduction of advanced tumors is associated with increased proliferation of the remaining tumor cells. Thus, appropriate preoperative chemotherapy should prevent both cell proliferation and the increase of resistant cells. The aim of the present study was to evaluate the efficacy and toxicity of primary chemotherapy (P-CT) in previously untreated patients with stage IV ovarian cancer (OC).

Patients and methods: Thirty-four patients with stage IV OC were treated from January 1993 to April 2000 with P-CT. Eligibility criteria included: histologically or cytologically confirmed, unresectable stage IV OC and performance status < or = 3. P-CT consisted of four courses of carboplatin, cyclophosphamide and epirubicin until October 1996, and paclitaxel, carboplatin thereafter. Surgery followed P-CT. After the operation patients received two further courses of chemotherapy that were tailored according to their individual response. Median (M) age was 61 years, range 32-73; median performance status was 2. A total number of 197 courses of CT were administered, median 5.7 per patient.

Results: Complete or partial response (CR, PR) was observed in 28 patients (response rate 82%, 95% CI: 65.4% to 93.2%), disease stability and progression (SD, PD) was observed in three and three patients, respectively. Median time to progression was 16.45 months (range 4.8-90.4+), median survival time was 28 months (range 4.5 - 90.4+): 1-year survival rate was 94%. Toxicity according to WHO: nausea and vomiting grade (G) 2, 30% of patients; gastrointestinal G 2-3, 20% of patients; alopecia G 3, 88% of patients; hematological G 3-4, 73% of patients; neurologic G 2, 12% of patients. Nine pathological CRs were observed.

Conclusion: Neoadjuvant treatment with CBDCA with either CTX and EPI or Taxol is feasible and shows activity in OC.

Stage IV ovarian cancer; Primary chemotherapy; Carboplatin; Cyclophosphamide; Epirubicin; Paclitaxel

[1] Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Willemse P.H., Veromorken J. B., van Lindert A C. et al.: "Long term survival in ovarian cancer". Eur. J. Cancer, 1991, 17(11), 1367.

[2] Kristensen G.. Trope C.: "Epighelial ovarian carcinom" Lancet, 1997, 349 (9045), 113.

[3] Perez R. P., Hamilton T. C., Ozols R. F.: "Resistance to alkylating agents and cisplatin: insight from ovarian carcinoma model systems". Pharmacol. Ther., 1990, 48 (1), 19.

[4] The ovarian cancer meta-analysis project: "Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis". J. Clin. Oncol., 1991, 9 (9), 1668.

[5] Advanced Ovarian Cancer Trialists Group: "Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials". Bt: Med. J.. 1991, 303 (6807), 884.

[6] Pelaez I., Lacave A. J.. Palacio I., Alvarez E., Cueva J. F., Muniz I. et al.: "Phase II trial of epirubicin at standard dose in relapse ovarian cancer". Eur. J. Cancer, 1996, 32A (5), 899.

[7] McGuire W. P., Hoskins W. J., Brady M. F.: "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage lII and stage IV ovarian cancer". N. Engl. J. Med., 1996, 334 (1), 1.

[8] du Bois A., Richter B., Warm M., Costa S., Bauknecht T., Uick H J. et al. for the AGO study group: "Cisplatin/paclitaxel vs carboplatin/ paclitaxel as 1st line treatment in ovarian cancer". Proc. Am. Soc. Clin. Oncol.. 1998, 17. 361a (Abstract 1395)

[9] Hortobagyi G. N., Buzdar. U., Strom E. A., Ames F. C., Singletary S. E.: "Primary chemotherapy for early and advanced breast cancer". Cancer Lett., 1995, 90 (1), 103.

[10] Kelsen D. P., Ginsberg R., Pajak T. F., Sheahan D. G., Gunderson L., Mortimer J. et al.: "Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer". N. Engl. J. Med.. 1998, 339 (27), 1979.

[11] Jacobs C.: "Adjuvant and neoadjuvant treatment of head and neck cancers". Semin. Oncol., 1991, 18 (6), 504.

[12] Schwartz P. E., Rutherford T. J., Chamber、J. T., Kohorn E. I.. Thiel R. P.: "Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival". Gynecol. Oncol., 1999, 72 (1), 93.

[13] O'Reilly M. S., Holmgren L.. Shing Y., Chen C., Rosenthal R. A .. Moses M. et al.: "Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma". Cell., 1994, 79 (2), 315.

[14] Holmgren L., O'Reilly M. S., Folkman J.: "Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression". Nature Med., 1996, 1 (2), 149.

[15] Calvert A.H.,N ewell D.R., Gumbrell L.A.,O R' eillyS .,Burnell M., Boxall F. E. et al.: "Carboplatin dosage: prospective evaluation of a simple formula based on renal function". J. Clin. Oneal., 1989, 7 (11), 1748.

[16] Miller A. B.,H oogstraten B.,S taquet M.,W inkler A.: "Reporting results of cancer treatment". Cancer, 1981, 47 (I), 207.

[17] Kaplan E. L.,M eier P.: "Nonparametric estimation from incomplete observations". J. Am. Stat. Ass., 1958, 53, 457.

[18] Bristow R. E., Lagasse L. D., Karlan B. Y.: "Secondary surgical cytoreduction for advanced epithelial ovarian cancer". Cancer, 1996, 78 (10), 2049.

[19] Griffiths C. T.: "Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma". Nat l. Cancer inst. Monogr., 1975, 42, 101.

[20] Chen S. S., Bochner R.: "Assessment of morbidity in pnmary cytoreductive surgery for advanced ovarian cancer". Gynecol. Oneal., 1985, 20 (2), 190.

[21] Vergote I., De Wever I.,T jalma W.,V an Gramberen M., Decloedt J., van Dam P.: "Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients". Gynecol. Oneal., 1998, 71 (3), 431.

[22] Hunter R. W.,A lexander N. D.,S outter W. P.: "Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?". Am. J. Obstet. Gynecol., 1992, 166 (2), 504.

[23] Bristow R. E.,M ontz F. J.,L agasse L. D., Leuchter R. S., Karlan B. Y.: "Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer". Gynecol. Oncol., 1999, 72 (3), 278.

[24] Shimizu Y., Hasumi K.: "Treatment of stage III and IV ovarian cancer-is neoadjuvant chemotherapy effective?". N ippon Sanka Fujinka Gakkai Zasshi, 1993, 45 (9), 1007.

[25] Jacob J. H., Gershenson D.M .,M orris M.,C opeland L. J., Burke T. W., W harton J. T.: "Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer". Gynecol. Oncol., 1991, 42 (2), 146.